AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca has initiated a significant clinical study titled ‘A Modular Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD9829 as Monotherapy or in Combination in Patients With CD123-Positive Hematological Malignancies.’ The study aims to evaluate the safety and effectiveness of AZD9829, a promising drug for treating CD123-positive hematological cancers.
The study is testing AZD9829, an intravenous drug, both as a standalone treatment and in combination with other therapies. Its primary goal is to determine the drug’s safety, tolerability, and preliminary antitumor activity in patients with CD123-positive malignancies.
This interventional study is designed as a non-randomized, open-label trial with a sequential intervention model. The primary purpose is treatment-focused, with no masking involved, allowing researchers to directly observe the effects of AZD9829.
The study officially started on January 31, 2024, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 21, 2025, indicating ongoing progress in the trial.
The outcome of this study could significantly impact AstraZeneca’s stock performance, as positive results may enhance investor confidence and market positioning in the competitive oncology sector. Investors should watch for updates, as successful trials could position AstraZeneca favorably against competitors.
The study is currently recruiting, with further details available on the ClinicalTrials portal.